Skip to main content

Our Company
- Leadership
Innovation & Products
Our Perspective
Our Impact
Partners
Careers

Photocure ASA: Annual general meeting held

Published: 26 June 2026

Oslo, Norway, 26 June 2026: Photocure ASA (OSE: PHO), held its annual general meeting on 26 June 2026 at 17:00 hours (CEST).

The minutes from the general meeting setting out the resolutions are attached hereto.

For further information, please contact:

Priyam Shah

Vice President Investor Relations

Tel: +17176815072

Email: priyam.shah@photocure.com

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

News and events

Photocure ASA: Annual general meeting held

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day

Photocure ASA - Notice of the Annual General Meeting 26 June 2026

Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Photocure ASA: Results for the first quarter of 2026

New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

Photocure ASA: Invitation to presentation of first quarter 2026 financial results

Photocure ASA: Annual Report 2025

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Blue Light Cystoscopy demonstrates cost neutrality through reduced recurrence in real-world BRAVO study

Update on KARL STORZ’s Citizen Petition

Asieris: Cevira Endorsed with Level 1A Evidence in Expert Consensus